Trial Profile

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avutometinib (Primary) ; Defactinib (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms RAMP 205
Sponsors Verastem Oncology

02 Sep 2025 Status changed from recruiting to active, no longer recruiting.
07 Aug 2025 According to a Verastem Oncology media release, the study has met the pre-defined criteria to advance beyond the first stage of the expansion study and enrollment is continuing in the expansion cohort for up to 29 patients at the RP2D. Company expects enrollment completion in expansion cohort in Q3 2025.
24 Jun 2025 Planned End Date changed from 31 Dec 2025 to 31 Aug 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com